24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Actavis
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
11:14
“In an agentic world, niche markets are no longer a constraint”
11:09
Senior engineer departs Sutskever’s Safe Superintelligence to launch Israeli AI trust startup
10:40
Israel signs $130 million deal with Elbit to outfit next-generation helicopters
10:02
Full list of Israeli startup M&As in 2026
More stories
Buzz
Most popular
Daily
Weekly
1
Israeli defense firms target Asia as Singapore Airshow opens amid regional arms race
2
Chinese fund: “The Chinese government has imposed a ban on any new investment in Israel”
3
Cyera employees to sell tens of millions in shares at $9 billion valuation
4
Israeli startup raises $6.2 million to turn social media video into intelligence
5
Medtronic to acquire Israeli AI cardiology firm CathWorks for $585 million, deal could reach $1 billion
More news
Actavis
5 stories about Actavis
Allergan Says Teva Bears Sole Liability for Actavis' Actions
02.09.19
|
Hezi Sternlicht
Actavis, which Teva bought from Allergan in 2016 for $40.5 billion, was one of the top U.S. sellers of opioids in 2006-2012
The Crucial Piece of Information Teva Overlooked
24.12.17
|
Sophie Shulman
When Teva went full force after Allergan's generic unit Actavis in what has become the company’s most costly acquisition, generic drug prices were already falling.
Teva Wants to Be Like Mylan: Agile, Lean and Profitable
17.12.17
|
Uri Tal-Tenne
The cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
Allergan Sketches Road Show to Sell Teva Stake
14.08.17
|
Golan Hazani
The company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter
Allergan Can Now Sell 9.8% Teva Stake
03.08.17
|
Dror Reich
Yesterday, a lock-up period on $3.2 billion worth Teva Pharmaceutical Industries’ shares owned by Allergan ended